Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)

Aquestive Therapeutics' (AQST) quarterly Asset Writedowns and Impairment came in at $6000.0 in Q3 2019, up 119.35% year-on-year from $2735.3 in Q3 2018, and down 75.0% quarter-over-quarter from $24000.0 in Q2 2019.

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019) Analysis & Trends

Aquestive Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $6000.0 for Q3 2019.

  • On a quarterly basis, Asset Writedowns and Impairment rose 119.35% year-over-year to $6000.0 in Q3 2019; TTM through Sep 2019 was $89000.0, a N/A change from a year earlier, with the FY2018 full-year figure at $53000.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment retreated to $6000.0 in Q3 2019 per AQST's latest filing, from $24000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $53000.0 in Q4 2018 and bottomed at -$31000.0 in Q3 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.06 Bn 87.19 Bn -
2 Teva Pharmaceutical Industries 35.92 Bn 32.18 Bn 1.97 Bn
3 Zoetis 32.51 Bn 30.57 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.56 Bn 23.49 Bn 4.39 Bn
5 United Therapeutics 23.18 Bn 21.03 Bn 648.10 Mn
6 RedHill Biopharma 21.76 Bn 21.76 Bn -
7 Viatris 20.28 Bn 18.48 Bn 1.16 Bn
8 Neurocrine Biosciences 17.75 Bn 16.43 Bn 800.70 Mn
9 Elanco Animal Health 12.63 Bn 12.21 Bn 785.00 Mn
10 Aquestive Therapeutics 462.85 Mn 462.85 Mn 13.47 Mn

Historic Data

Download Data
DateValue
Sep 30, 2019 6,000.00
Sep 30, 2019 6,000.00
Jun 30, 2019 24,000.00
Jun 30, 2019 24,000.00
Mar 31, 2019 6,000.00
Mar 31, 2019 6,000.00
Dec 31, 2018 53,000.00
Dec 31, 2018 53,000.00
Sep 30, 2018 -31,000.00
Sep 30, 2018 -31,000.00